The background could be extended to give the International reader a better understanding of current practice in Japan. It is stated the current treatment is UFH transitioning to warfarin. Are LMWH or fondaparinux (mentioned later) not approved in Japan for VTE treatment. The authors should describe the approved rivaroxaban treatment for VTE in Japan. Is there a creatinine clearance limitation? What is the rationale for the 15 mg. Compare the Japanese dosing with the rest of the world. How will selection bias be minimised at recruitment? What are the exclusion criteria? Will consecutive eligible patients be included. In the outcome assessments, The definition of clinically relevant not major bleeding is missing. Fatal bleeding should be included in major bleed definition. The authors need to make clear what a rivaroxaban treated patient is :-Patient treated with rivaroxaban alone Up to 48 hours of parenteral therapy then rivaroxaban (Einstein protocol) What if the patient has >48 parenteral therapy (will this affect the outcome, ?more bleeding. Are they the PE patients ?) Have the authors considered the impact of Einstein Choice (rivaroxaban 10 mg) on treatment choices. There are syntax and spelling errors that require correction…..e.g. rivaroxsaban
VERSION 1 -AUTHOR RESPONSE

Reviewer(s)' Comments to Author:
Reviewer: 1 Reviewer Name: Paolo Prandoni Institution and Country: Arianna Foundation on Anticoagulation, Bologna, Italy Please state any competing interests or state 'None declared': None declared Please leave your comments for the authors below Although I fully respect the opinion of the authors, and congratulate them for their enthusiasm, the study protocol should not be published in an internationally respected journal such as the BMJ for at least five reasons: 1) rivaroxaban has not been tested for the treatment of asymptomatic VTE.
Reply
We agree with your comments that the subjects in the Phase III study had only symptomatic VTE. The regimen of rivaroxaban in Japan does not restrict the use of rivaroxaban for symptomatic VTE. The EMA and FDA do not restrict symptomatic patients for an indication of the use of VTE either, however, they stated that the subjects of the EINSEIN PE/DVT study were eligible as symptomatic VTE patients. In the real world clinical practice, it would be expected that there would be some asymptomatic patients. In fact, the PMS data in Japan showed 93/216 (43.1%) patients with PE and 144/402 (35.8%) patients with DVT were asymptomatic, in whom the DVTs were incidentally detected by lower-extremity venous ultrasonography or CT images. This study was a prospective survey of Japanese VTE patients, so one of the aims of this study was to examine the clinical outcomes in such patients, which were not tested in the phase III studies.
This has been added in the introduction section as follows (page 6, lines 6-17): Further, the regimen of the use of rivaroxaban in Japan does not restrict the inclusion to just symptomatic DVT/PE, and thus, rivaroxaban may be clinically used in specific patients such as those that are asymptomatic, have isolated distal DVT, or have cancer that has not been validated in the phase III trials of the EINSTEIN-DVT/PE study3-5 and J-EINSTEIN study.6 We, therefore, established a multicenter registry, which we refer to as the J'xactly Study (Japanese registry of rivaroXAban effectiveness & safety for the prevention of reCurrence in patients with deep vein Thrombosis and puLmonarY embolism), to support prospective observational research aimed at clarifying the effectiveness and safety of rivaroxaban for clinical use in Japanese patients with VTE (UMIN000025072, NCT03091621) including symptomatic/asymptomatic VTE, isolated distal DVT, and cancer-associated VTE. The rationale for and design of the first J'xactly Study are described herein.
We also added the following sentences in the discussion section (page 15, lines 6-16): The phase III trials in the EINSTEIN-DVT/PE targeted patients with acute symptomatic VTE.3-5 A pooled subgroup analysis of those trials revealed a similar efficacy and safety compared to treatment with enoxaparin and a vitamin K antagonist in patients with active cancer and VTE, but the number of subjects was small.17 Because rivaroxaban use was not restricted to patients with symptomatic acute VTE in Japan, rivaroxaban will be widely used not only in acute symptomatic VTE patients but also in patients such as those with asymptomatic VTE or isolated distal DVT incidentally detected by lowerextremity venous ultrasonography or cancer-associated VTE in clinical practice. It remains to be elucidated whether rivaroxaban use will be clinically acceptable for VTE treatment in specific patients such as those with cancer-related VTE or asymptomatic VTE. This study will provide the information needed to answer the questions raised.
2) The use of 15 mg once daily is not acceptable. Subanalyses of the Einstein studies have clearly shown that the standard 20 mg once daily is associated with a high benefit-to risk profile even in low body weight individuals. In addition, not all Japanese patients have a low body weight Reply Yes, I agreed with your point. Nonetheless, a pooled analysis of the EINSTEIN-DVT and PE randomized studies included only 42 and 66 patients with a body weight of < 50kg in the rivaroxaban and enoxaparin/VKA groups. In those groups, the efficacy in the rivaroxaban group was statiscally equal to enoxaparin/VKA (7.1% vs. 3.0%, the incidence and hazard ratio were better for the enoxaparin/VKA group vs. rivaroxaban group), but the safety was not determined because of too small a number of clinical events. From a statistical point of view, it remains to be established whether rivaroxaban 20 mg once daily offers an advantage over the enoxaparin/VKA therapy. The continuous therapy dose regimen of 15 mg for VTEs was chosen and approved in Japan according to the following background: Based on rivaroxaban pharmacokinetics in Japanese subjects and lower anticoagulation in Japan, the standard dose regimen for Japanese AF patients was 15 mg once daily (We added a new reference #7. Tanigawa T, Kaneko M, Hashizume K, Kajikawa M, Ueda H, Tajiri M, et al. Drug Metab. Pharmakinet. 2013; 28: 59-70.) . The Japan-specific rivaroxaban dose tested in the J-ROCKET AF study demonstrated the non-inferior of major bleeding and strokes/systemic embolisms to warfarin therapy, which supports bridging the global ROCKET AF results into Japanese clinical practice. Then, rivaroxaban 15 mg once daily was firstly approved for atrial fibrillation. Thereafter, J-EINSTEIN for PE and DVT patients was conducted. The J-EINSTEIN study was an open-label, randomized trial that compared 3, 6, or 12 months of oral rivaroxaban alone (10 mg twice daily or 15 mg twice daily for 3 weeks followed by 15 mg once daily) with activated partial thromboplastin time-adjusted intravenous unfractionated heparin (UFH) followed by warfarin in patients with acute, objectively confirmed symptomatic DVTs and/or PEs. The findings of the J-EINSTEIN study in Japanese patients with acute DVTs and/or PEs suggest a similar efficacy and safety profile with rivaroxaban and control treatment. The approved date of rivaroxaban for atrial fibrillation was for atrial fibrillation first and then for VTEs, which was opposite that in Western countries. The 15 mg once daily was the principal dose for Japanese but not for a low body weight. This is an off-label dose for Western and other Asian people, but as described above, there would not have been any evidence fully supporting the efficacy and safety of a 20 mg continuous therapy dose for low body weight VTE patients. Therefore, the Japan-specific dose should provide clinical insight into understanding VTE treatment in some Western and Asian patients with a similar body type as Japanese people. This specific background in Japan was addressed in the introduction (page 5, line 19-page 6, line 6): Several specific situations exist for the VTE treatment in Japan. Low molecular weight heparin is not approved in Japan, so the current treatment is unfractionated heparin (UFH) or fonda-parinux transitioning to warfarin. As compared to Western countries, a lower continuous therapy dose of 15 mg once daily has been chosen and approved in Japan because it is based on rivaroxaban pharmacokinetics in Japanese subjects.7 The continuous therapy dose of 15 mg was tested in Japanese patients in the J-EINSTEIN study, and this study showed a similar efficacy and safety profile as rivaroxaban and warfarin control treatment, however, that trial for the treatment of DVTs/PEs included few Japanese patients.6 In addition, there have been no other countries that have used this Japan-specific continuous therapy dose for the treatment of VTEs. Such a situation requires real world evidence on the benefit of rivaroxaban in Japanese VTE patients.
We also added the potential clinical insight of our data in the discussion section (page 14, line 24-page 15, line 5); A pooled analysis of the EINSTEIN-DVT and PE randomized studies included only 42 patients of a body weight of < 50kg in the rivaroxaban groups,5 and thus, there are few data supporting the efficacy and safety of rivaroxaban 20 mg once daily for low body weight VTE patients even in Western and Asian people. More data on the effectiveness and safety of the Japan-specific dose will also provide clinical insight into understanding the VTE treatment in some Western and Asian patients that have a similar body type to Japanese people.
Japanese patients with atrial fibrillation revealed that physicians tended to reduce the DOAC dose down to 10 mg as a precaution against future bleeding events.20,21 This is also expected to happen in the VTE treatment in Japan. Therefore, the long follow-up period and the dose of rivaroxaban in clinical practice will allow us to determine the optimum evidence-based duration and dose of rivaroxaban therapy in a diverse population of Japanese patients with DVT/PE. 4)-rivaroxaban has not been tested for the treatment of isolated distal DVT 5)-rivaroxaban cannot (yet) be used for the treatment of patients with cancer-associated thrombosis Reply As pointed out, rivaroxaban was tested only for symptomatic VTE patients in the EINSTEIN-DVT and PE studies and J-EINSTEIN study. Nonetheless, a pooled subgroup analysis of the EINSTEIN-DVT and -PE had 655 (8%) patients with any type of active cancer and 469 (6%) with a history of cancer among 4150 patients randomly assigned to receive rivaroxaban. In that study, the patients with acute venous thromboembolisms had a similar efficacy of a single drug approach with oral, fixed-dose rivaroxaban as a combination of a subcutaneous enoxaparin and INR titrated therapy with a vitamin K antagonist in patients with cancer, and consistent results across all important clinical subgroups. Therefore, the rivaroxaban use would be potentially useful for patients with cancer, although the longterm efficacy and safety remain to be elucidated. The PMS data in Japan also included 76/545 (14.1%) patients with cancer-associated VTEs. This study is a real world survey and did not exclude the patients with isolated distal DVTs or those with cancer, so some of the enrolled patients would have had isolated distal DVTs or cancer. Again, this study was an observational survey to clarify the clinical events associated with rivaroxaban for the clinical use in Japanese patients with VTEs, so one of the aims of this study was to clarify the clinical events in such specific patients as those with isolated distal DVTs or cancer. This was added in the introduction section as a response to comment #1.
Reviewer: 2 Reviewer Name: Alexander G G Turpie Institution and Country: Emeritus Professor, McMaster University, Hamilton ON, Canada Please state any competing interests or state 'None declared': Consultant to Bayer. PI of a similar Phase IV study of VTRE treatment with rivaroxaban Please leave your comments for the authors below This is a manuscript of the design and rational of a descriptive study of VTE treatment with rivaroxaban in Japanese patients. The rational is presented in the introduction but there appears to be a bit of confusion between prevention and treatment of VTE (refs 3-6) . The strengths and limitations in the introduction should be more clear. For example, which are the strengths and which are the limitations. The background could be extended to give the International reader a better understanding of current practice in Japan. It is stated the current treatment is UFH transitioning to warfarin. Are LMWH or fondaparinux (mentioned later) not approved in Japan for VTE treatment. The authors should describe the approved rivaroxaban treatment for VTE in Japan. Is there a creatinine clearance limitation? What is the rationale for the 15 mg. Compare the Japanese dosing with the rest of the world.
We appreciate your adequate advice. We did not describe the specific situation in Japan in the previous text, so we have added the specific background in the introduction section to make the strengths and limitations more clear as follows (page 5, line 19-page 6, line 6): Several specific situations exist for the VTE treatment in Japan. Low molecular weight heparin is not approved in Japan, so the current treatment is unfractionated heparin (UFH) or fonda-parinux transitioning to warfarin. As compared to Western countries, a lower continuous therapy dose of 15 mg once daily has been chosen and approved in Japan because it is based on rivaroxaban pharmacokinetics in Japanese subjects.7 The continuous therapy dose of 15 mg was tested in Japanese patients in the J-EINSTEIN study, and this study showed a similar efficacy and safety profile as rivaroxaban and warfarin control treatment, however, that trial for the treatment of DVTs/PEs included few Japanese patients.6 In addition, there have been no other countries that have used this Japan-specific continuous therapy dose for the treatment of VTEs. Such a situation requires real world evidence on the benefit of rivaroxaban in Japanese VTE patients. Further, the regimen of the use of rivaroxaban in Japan does not restrict the inclusion to just symptomatic DVTs/PEs, and thus, rivaroxaban may be clinically used in specific patients such as those that are asymptomatic, have isolated distal DVT, or have cancer that has not been validated in the phase III trials of the EINSTEIN-DVT/PE study3-5 and J-EINSTEIN study.6
Contraindication of the use of rivaroxaban was included in the Population section (page 8, line 10): Patients with severe renal impairment with a creatinine clearance [CrCl] <30mL/min How will selection bias be minimised at recruitment? What are the exclusion criteria? Will consecutive eligible patients be included.
Reply Yes, this study will enroll consecutive patients. The exclusion criteria are contraindication to the use of rivaroxaban, and those with active bleeding and those who fail to provide written informed consent. To minimize the selection bias, all patients treated with rivaroxaban that met the inclusion criteria but not the exclusion criteria will be enrolled. Accordingly, we have indicated the patient selection more clearly as follows (page 8, lines 3-21): The study enrolls consecutive patients eligible if acute symptomatic/asymptomatic DVTs or PEs or both have been diagnosed and rivaroxaban has been started for the treatment and prevention of VTEs. Patients not eligible for enrollment are those with a condition that contraindicates the use of rivaroxaban (significant hepatic disease, including moderate to severe hepatic impairment, i.e. ChildPugh B and C, a systolic blood pressure of more than 180 mm Hg or a diastolic blood pressure of more than 110 mm Hg; childbearing potential without proper contraceptive measures, pregnancy, or breastfeeding, undergoing dialysis or patients with severe renal impairment with a creatinine clearance [CrCl] of <30mL/min, concomitantly treated with strong inhibitors of both CYP 3A4 and Pglycoprotein, such as HIV protease inhibitors [e.g. ritonavir] or systemically administered azole antimycotics [e.g. ketoconazole]), those with chronic thromboembolic pulmonary hypertension (CTEPH) (but those with CTEPH plus an acute PE or DVT are eligible), and those with active bleeding. Patients who fail to provide written informed consent and those who are deemed noncompliant will not be enrolled. To minimize the selection bias, all patients treated with rivaroxaban meeting the inclusion criteria, but not the exclusion criteria will be enrolled. Therefore, the eligible patients include those who have clinical events prior to the enrollment from the start of rivaroxaban, those with an isolated distal DVT or cancer-associated VTE, or those treated with non-standard regimens or off-label doses of rivaroxaban (e.g. 10 mg twice daily for an acute therapy dose or 10 mg once daily for a continuous therapy dose).
In the outcome assessments, the definition of clinically relevant not major bleeding is missing. Fatal bleeding should be included in major bleed definition.
Thank you for your important comment. Clinically relevant non-major bleeding is defined as overt bleeding that did not meet the criteria for major bleeding but was associated with medical intervention, unscheduled contact with a physician, interruption or discontinuation of a study drug, or discomfort or impairment of the activities of daily life. Fatal bleeding is included in major bleed definition. Those were addressed in the revised paper (page 12, lines 19-23): Major bleeding is defined as a reduction in the hemoglobin level of at least 2 g/dL, transfusion of at least 2 units of blood, or symptomatic bleeding in a critical area or organ or fetal bleeding. Clinically relevant non-major bleeding is defined as overt bleeding that does not meet the criteria for major bleeding but is associated with medical intervention, unscheduled contact with a physician, interruption or discontinuation of a study drug, or discomfort or impairment of activities of daily life.6
The authors need to make clear what a rivaroxaban treated patient is :-Patient treated with rivaroxaban alone Up to 48 hours of parenteral therapy then rivaroxaban (Einstein protocol) What if the patient has >48 parenteral therapy (will this affect the outcome, ?more bleeding. Are they the PE patients ?) Reply Thank you for your important advice. As commented, the duration and type of therapy before rivaroxaban will affect the outcome. From that viewpoint, we will classify the rivaroxaban treated patients into 4 groups: 1) rivaroxaban is received according to the standard regimen (After a diagnosis of a DVT or PE, patients will be given 15 mg of oral rivaroxaban twice daily for 3 weeks and then 15 mg once daily thereafter), 2) UFH or fonda-parinux is administered first for a maximum of 48 h before enrollment, and then rivaroxaban twice daily and once daily thereafter (EINSTEIN protocol), 3) UFH or fonda-parinux is administered first for at least 2-14 days, and then warfarin (or rivaroxaban twice daily or other direct oral anticoagulants [DOACs]), and then rivaroxaban once daily thereafter, and 4) only rivaroxaban once daily is administered or switched from warfarin (or other DOACs) without any parenteral therapies or acute treatment of rivaroxaban twice daily. This was now added in the revised paper (page 9, lines 5-12).
Have the authors considered the impact of Einstein Choice (rivaroxaban 10 mg) on treatment choices. Reply Unfortunately, Japan did not participate in the EINSTEIN CHIOCE study. The J'xactly was designed before the results of the EINSTEIN CHIOCE study, and thus, we did not actually consider the impact of the EINSTEIN CHOICE study. Nonetheless, as described in the prior text, the real data obtained on the use of DOACs in patients with atrial fibrillation revealed that physicians tended to reduce the DOAC dose down to 10 mg as a precaution against future bleeding events. This is also expected to happen in the J'xactly study. If this often occurs, the pooled data of 10 mg rivaroxaban dose may provide clinical insights into understanding a low dose of rivaroxaban in the patients with weak risk factors. This is included in the discussion section as follows (page 16, lines 1-11): Recently, the EINSTEIN CHOICE study showed an equivalent efficacy between a 20 mg dose and 10 mg dose of rivaroxaban, which ar superior to asprin without an increase in major bleeding in patients who completed the 6-12 month VTE treatment.19 This raises a question of whether patients with unprovoked VTEs or VTEs associated with weak risk factors should receive 10 mg once daily in the chronic phase. The real world data obtained on the use of DOACs in Japanese patients with atrial fibrillation revealed that physicians tended to reduce the DOAC dose down to 10 mg as a precaution against future bleeding events.20,21 This is also expected to happen in the VTE treatment in Japan. Therefore, the long follow-up period and the dose of rivaroxaban in clinical practice will allow us to determine the optimum evidence-based duration and dose of rivaroxaban therapy in a diverse population of Japanese patients with DVTs/PEs.
There are syntax and spelling errors that require correction…..e.g. rivaroxsaban Reply Thanks. We corrected it.
FORMATTING AMENDMENTS (if any) Required amendments will be listed here; please include these changes in your revised version:
Finally, this study is now ongoing smoothly and the enrollment will end in May this year. Unexpectedly, we have waited 3 months after the initial submission (in October, 2017) to receive this revision of this design paper. We have carefully considered all of the reviewers' comments and have made the significant changes as far as we could do. Considering the characteristics for the design paper, we have to complete this design paper before the deadline of the patient enrollment. Please consider our enthusiasm and challenges when this paper is judged. We hope that has substantially improved in the manuscript and look forward to your final decision. GENERAL COMMENTS -The reviewer provided a marked copy with additional comments. Please contact the publisher for full details.
VERSION 2 -AUTHOR RESPONSE
Reviewer #2
Design of → Design Abstract 1． The reviewer asked us the reasons why a real-world survey of Japanese patients being treated with rivaroxaban for VTE is needed.
Because there is little data regarding VTE treatment in Japan, a real-world survey of Japanese patients being treated with rivaroxaban for VTE is needed (page 2, lines 5,6).
2．
The reviewer indicated us to delete the "variable". The primary efficacy outcome is symptomatic recurrent VTE occurring during the study period. The principal safety outcome is clinically relevant bleeding (page 2, lines 14, 15)
The reviewer required us to state the strengths and limitations of this study more clearly.
Accordingly, we modified the strengths and limitations section in the following sentences (page 4):
This is the largest ongoing prospective observational research study with a great statistical power to investigate the clinical outcomes of one of the direct oral anticoagulants (rivaroxaban) for clinical use in Japanese patients with VTE. This study will provide important information on the use of rivaroxaban in Japanese patients with VTE, including symptomatic/asymptomatic VTE, isolated distal DVT, or cancer-associated VTE.
Japan approved a specific continuous therapy dose of rivaroxaban (15 mg once daily) for VTE prevention, which is lower than that (20mg once daily) in other Asian or Western countries. The dosedifference should be considered when interpreting our results.
Because of no interference with the clinical decision-making process by physicians and patients, the duration or dose of the rivaroxaban use or the VTE subjects enrolled in this study will vary.
As this study included only patients treated with rivaroxaban and no concurrent control arm for a comparison, we will be unable to elucidate the effectiveness of rivaroxaban as compared to the current treatment in Japan such as with the use of unfractionated heparin or fondaparinux transitioning to warfarin.
INTRODUCTION
Background and rationale 1. The reviewer indicated us to distinguish the VTE treatment from the prevention. We changed the "in many countries for the treatment and prevention of VTE".
2. The reviewer recommended us to change the "to be non-inferior" from the "not to be inferior". Did it. Thanks 3. The reviewer indicated a typo of the "fonda-parinux". We corrected the "fondaparinux" throughout the revised text.
4. The reviewer asked us the detailed description of J-EINSTEIN study. We modified that sentence as follows (page 5, line 24-page 6, line 2): The 15 mg twice daily dose for a total of 3 weeks and then, a continuous therapy dose of 15 mg, were tested in Japanese patients in the J-EINSTEIN study.
5. As recommented, we inserted the sentences of the discussion section in the rationale section (page 6, lines 5-10). A pooled analysis of the EINSTEIN-DVT and PE randomized studies included only 42 patients of a body weight of < 50 kg in the rivaroxaban groups.5 As the Western and Asian countries have approved a 20 mg once daily dose as a continuous therapy dose for the prevention of VTE, it remains unclear whether that dose regimen is suitable for low body weight patients such as Japanese people in other countries. Such a situation requires real world evidence on the benefit of a specific rivaroxaban dose in Japanese VTE patients.
6. The reviewer indicated a typo of the "that has not been validated in the phase III".
We corrected the typo as follows (page 6, line 13): that have not been validated in the phase III
METHODS AND ANALYSIS
Study design
The reviewer indicated a typo of the sentence: in Japanese patients with acute DVT who are treated with rivaroxsaban in real-world clinical practice
We modified and corrected the following sentence (page 7, lines 7,8) : in Japanese patients with acute DVT or PE or both who are treated with rivaroxaban in real-world clinical practice
Population
The reviewer recommended us to modified the sentence of the "been started for the treatment and prevention of recurrent VTE" (page 8, line 10). Did it. Thanks.
Treatment
The reviewer questioned whether the rivaroxaban dose of 10mg was approved in Japan or not. Yes, the 10 mg dose was approved in Japan but this dose regimen should be considered if the patients are concomitantly treated with fluconazole, posaconazole, clarithromycin, or erythromycin. This was addressed in the treatment section (page 8, lines 10,11): This is a standard regimen. After a diagnosis of DVT or PE, patients will be given 15 mg of oral rivaroxaban twice daily for 3 weeks and then 15 mg once daily thereafter (a continuous dose of 10 mg once daily should be considered only if the patients are concomitantly treated with fluconazole, posaconazole, clarithromycin, or erythromycin).
Outcome assessments
We corrected the typo of the fetal bleeding to the "fatal bleeding" (page 12, line 3).
Statistical methods
The reviewer indicated the outcome analyses was wrong because the primary outcome should an be on-treatment analysis.
We modified it as follows (page 12, lines 12-16):
The primary efficacy and secondary outcome analyses will be carried out in an intention-to-treat population, defined as all participants who receive at least one dose of rivaroxaban, and will include all primary efficacy events occurring from the time of patient enrollment to the end of the survey period. The primary safety outcome analysis will be carried out in an on-treatment population.
Sample size
The reviewer questioned whether the rivaroxaban dose of 10mg was approved in Japan or not. Yes, the 10 mg dose was approved in Japan but this dose regimen should be considered if the patients are concomitantly treated with fluconazole, posaconazole, clarithromycin, or erythromycin. This was addressed in the treatment section.
Discussion
The reviewer indicated the sentences "The efficacy and safety of this rivaroxaban regimen ….. 20 mg once daily for low body weight VTE patients even in Western and Asian people" should be up-front in the rationale section. We deleted it and did it accordingly.
The reviewer indicated the discussion was too long.
As commented, we shortened the discussion section from 1069 words to 870 words.
VERSION 3 -REVIEW
REVIEWER
Alexander G G Turpie McMaster University, Hamilton ON Canada REVIEW RETURNED 12-Apr-2018
GENERAL COMMENTS
Improved, but this observational study cannot determine efficacy and safety as stated in the objectives. Also the Authors are still confused regarding prevention vs treatment"
VERSION 3 -AUTHOR RESPONSE
Reviewer #2 Comment #1. this observational study cannot determine efficacy and safety as stated in the objectives. We deleted the "efficacy", and changed it to the "effectiveness" if needed. We corrected the sentences throughout. Please see below.
Abstract The J'xactly study has been established to clarify the efficacy and safety of rivaroxaban for the prevention of symptomatic recurrent VTE (page 2, lines 10-12): The J'xactly study has been established to investigate the clinical outcomes of rivaroxaban for the initial treatment and prevention of symptomatic recurrent VTE in Japanese patients with acute symptomatic/asymptomatic VTE. The primary efficacy outcome is symptomatic recurrent VTE occurring during the study period. (page 2, line 15): The primary outcome is symptomatic recurrent VTE occurring during the study period.
Study objectives
The aim of the J'xactly Study is to clarify the clinical outcomes of the use of rivaroxaban over the long term in Japanese patients being treated with the drug for acute VTE. (page 7, lines 1-2): The aim of the J'xactly Study is to investigate the clinical outcomes of the use of rivaroxaban for the initial treatment of acute VTE and prevention of recurrent VTE in Japanese patients with acute VTE.
Outcome assessment
The primary efficacy outcome variable in this study is symptomatic recurrent VTE, (page 11, line 11):
The primary outcome variable in this study is symptomatic recurrent VTE,
Statistical methods
The primary efficacy and secondary outcome analyses will be carried out in an intention-to-treat population, defined as all participants who receive at least one dose of rivaroxaban, and will include all primary efficacy events occurring from the time of patient enrollment to the end of the survey period. The primary safety outcome analysis will be carried out in an on-treatment population (page 12, lines 12-16): The primary and secondary outcome analyses will be carried out in an intention-totreat population, defined as all participants who receive at least one dose of rivaroxaban, and will include all primary and secondary events occurring from the time of patient enrollment to the end of the survey period. The principal safety outcome analysis will be carried out in an on-treatment population.
DISCUSSION
The study will also provide important insight into the efficacy and safety of DOAC rivaroxaban for treatment of VTE and into the prognosis of VTE.(page 13, lines 3-5): The study will also provide important insight into the effectiveness and safety of DOAC rivaroxaban for treatment of VTE and into the prognosis of VTE.
Comment #2. Authors are still confused regarding prevention vs treatment As pointed out, we have addressed the "initial treatment of acute VTE and prevention of recurrent VTE" to distinguish between the treatment and prevention more clearly. The parts that we corrected are described below:
INTRODUCTION Background and rationale it has been approved in many countries for the treatment and prevention of VTE in at-risk adults.
(page 5, lines 12-13): it has been approved in many countries for the initial treatment of acute VTE and prevention of recurrent VTE in at-risk adults.
Several specific situations exist for the VTE treatment in Japan. (page 5, line 20): Several specific situations exist for the initial treatment and long-term treatment of VTE in Japan.
the current treatment is unfractionated heparin (UFH) or fondaparinux transitioning to warfarin. (oage 5, lines 21-22): Low molecular weight heparin is not approved in Japan, so the current initial treatment of acute VTE is unfractionated heparin (UFH) or fondaparinux transitioning to warfarin.
a lower continuous therapy dose of 15 mg once daily has been chosen and approved in Japan (page 5, lines 222-23): As compared to Western countries, a lower continuous therapy dose of 15 mg once daily for the prevention of recurrent VTE has been chosen and approved in Japan
As the Western and Asian countries have approved a 20 mg once daily dose as a continuous therapy dose for the prevention of VTE (page 6, lines 6-8): As the Western and Asian countries have approved a 20 mg once daily dose as a continuous therapy dose for the prevention of recurrent VTE
Study objectives
